Economic Observation Network The core product of Jinfang Pharma-B has been recognized by the research report of Shenwan Hongyuan, and there is still a demand for rebound after the stock price correction. There is still uncertainty in research and commercialization.

Institutional perspective:
Recently, Shenwan Hongyuan released a research report emphasizing that its core product GFH375 (oral KRAS G12D inhibitor) has been preliminarily validated for efficacy and safety advantages in Phase I/II clinical trials,Having the best potential in the same categoryAnd is expected to be listed in China in 2028 This strengthens the market's confidence in the value of the company's pipelines.

Recent stock trends:
After soaring at the end of April, the company's stock price experienced a deep correction for nearly two months, almost giving up all the gains of the year Under the stimulation of favorable industry conditions, there is a demand for technical rebound.

Future Development:
The Phase III clinical data of the core pipeline GFH375, future medical insurance negotiation prices, and market competition (there are already four KRAS G12C inhibitors in China) are all key variables 。

The above content is based on publicly available information and does not constitute investment advice.